Peter Fong serves as Senior Manager of New Ventures and Business Development in the Office of Technology Development, where he also administers Memorial Sloan-Kettering’s Technology Development Fund.
Peter received a PhD degree in biomedical engineering in 2003 from Yale University. His distinctions while at Yale include a Brown-Coxe Postdoctoral Fellowship.
Prior to joining Memorial Sloan-Kettering as a licencing manager in 2009, Peter was involved in four start-ups at the founding equity level, including Carigent Therapeutics, Inc., which was spun out of Yale University. He served as the company’s cofounder and interim CEO during its initial launch and pre-financing stage, and as head scientist and board member after the company completed its $2 million Series A financing. At Memorial Sloan-Kettering, Peter has been involved in the formation of a number of new ventures as well.
From 2005 through 2007, Peter served as an expert consultant to a US law firm involved with intellectual property litigation related to advanced drug delivery devices. Previously, he worked as a Six-Sigma certified product developer at General Electric, where he managed a portfolio of three global GE polymer products.
Peter is a co-inventor on 12 issued or pending patents, some of which have been exclusively licensed to two biotech companies to six life science companies, including Amgen, Pfizer, and Bind Therapeutics.